CoV Assistance Program: Are you or someone you know currently researching the COVID-19 outbreak? Rockland is here to help. Register to receive complimentary CoV antibodies, 40% off related products, and/or 20% off related services. Let’s work together to end this pandemic. Register now >>

Coronaviruses (CoV) are a family of viruses that range from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). The current outbreak is attributed to a novel coronavirus (COVID-19), which is a new strain not previously identified in humans and believed to have originated in bats. However, human-to-human transfer is occuring via droplet inspiration, as is the case with most respiratory viruses.

The outbreak of COVID-19 was declared a public health emergency of international concern by the WHO, pressuring researchers worldwide to develop a treatment. As a trusted provider to the research community, Rockland has products and services that support the study of COVID-19 including:

Specific antibodies capable of detecting the 2019-nCov.

Due to high homology with the 2002 SARS-CoV, existing antibodies to SARS may provide the means of detection. Our antibodies shown below were developed from immunogen material for the detection of SARS-CoV with high homology to the current coronavirus outbreak—cross reactivity can be expected based on the amino acid sequences.

Determination of the correct host cell for 2019 nCoV to infect and grow in culture.

Once suitable cell lines are determined for infectivity, antibodies against 2019-nCoV can be tested for their ability to neutralize infection. Vero E6 cells have been demonstrated to be suitable for SARS-CoV.

Identification of the receptor that binds 2019-nCoV.

For SARS-CoV, the ACE2 receptor was identified as the mechanism for the virus entering cells. Whether ACE2 is the means of entry for 2019-nCoV has not yet been determined; however, antibodies against ACE2 and other receptors are critical to understanding the mechanism of infection.

Rapid development of novel antibodies specific for 2019-nCoV using engineered immunogens.

Monoclonal antibodies may be best suited to generate a highly specific immune response to specific domains within 2019-nCoV proteins such as the nucleocapsid; however, polyclonal antibodies are the best approximation of the natural immune defense system and may be good candidates for use in neutralization assays.